

## Recommendations for State of Wisconsin to Distribute a Multiple Dose COVID-19 Vaccine

The Vaccine Distribution Subcommittee (“Subcommittee”) of the State Disaster Medical Advisory Committee (SDMAC) was established to develop guidance for the Department of Health Services (DHS) regarding allocation of limited numbers of vaccine doses during the COVID-19 pandemic. At the present time, no SARS-CoV-2 vaccine is available in the United States, but several candidate vaccines are in development and under study in phase 3 clinical trials. It is anticipated that one or more vaccine products will be authorized or approved for use in the United States during the next several weeks to months. The initial quantity of vaccine doses available will be small in relationship to the number of people eligible to receive it, and therefore, rationing of available vaccine will be necessary until production and distribution increases in amounts sufficient to meet all needs.

The Subcommittee was tasked with answering the following question:

*If immunization requires a multiple-dose series will DHS recommend providing additional doses to individuals to complete a series, recommend more individuals receive a first dose, or leave the decision to the discretion of local providers?*

The Centers for Disease Control and Prevention (CDC) will determine Wisconsin's allocation of US vaccine supply. Guidance on how vaccine doses will be allocated to the States has been clarified by CDC. The Subcommittee was informed that in the case of a two-dose series, CDC will withhold a portion of Wisconsin's allocation for the purpose of providing a second dose; therefore, Subcommittee recommends using initial allocations to administer first dose to eligible population(s) with subsequent doses coming from the allocation CDC withholds for the purpose of second doses. Second doses from the withheld CDC allocation will be reserved for, and provided to, vaccinating entities who will immunize those who received the first dose and choose to receive the second.

The Subcommittee agrees with the DHS provider agreement that requires all vaccinators to comply with “all requirements and recommendations of CDC and CDC’s Advisory Committee on Immunization Practices (ACIP) and Food and Drug Administration (FDA) guidance relating to timing of the vaccination.” Currently, **ACIP has not provided any requirements or recommendations**, so the Subcommittee recommends for planning purposes that DHS and vaccinators anticipate that the products will not be interchangeable; therefore, a complete vaccine series will be defined as two doses from the same vaccine product is administered for both doses, if applicable in accordance with the ACIP schedule.